StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX)

StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research report issued on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Price Performance

NASDAQ:JAGX opened at $5.38 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. The firm’s fifty day moving average price is $16.83 and its 200 day moving average price is $23.42. Jaguar Health has a 1-year low of $4.90 and a 1-year high of $540.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC purchased a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned about 0.22% of Jaguar Health at the end of the most recent reporting period. Institutional investors own 12.04% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.